Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at

BASEL, Switzerland – 11th April 2022 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented yesterday in...

Related Keywords

United States , Switzerland , American , Marwang Fakih , Elisa Scarselli , American Association For Cancer Research , Society For Immunotherapy Of Cancer , Late Breaking , Cancer Research , Microsatellite Instable High , Annual Meeting , Medical Oncology Specialist , Duarte California , Chief Scientific Officer ,